Multivitamins have been tested more thoroughly than most supplements, in large randomised trials running over years. The results are worth knowing in detail, because they are consistent and because they are rarely mentioned on packaging.
What were the major trials?
The Physicians Health Study II followed more than 14,000 male doctors for over a decade, comparing a daily multivitamin against placebo.
It found a small reduction in total cancer incidence, around eight per cent, and no reduction in cardiovascular events, myocardial infarction or stroke. The cancer finding was modest and has not been convincingly replicated elsewhere.
Other large studies, including analyses within the Womens Health Initiative, found no significant effect on cancer or cardiovascular disease.
What did the reviews conclude?
Systematic reviews pooling multiple trials have generally found no reduction in all cause mortality, cardiovascular disease or cancer from multivitamin use in generally healthy adults.
The United States Preventive Services Task Force concluded the evidence was insufficient to recommend multivitamins for preventing cardiovascular disease or cancer, and recommended against beta carotene and vitamin E supplements specifically.
UK guidance similarly does not recommend multivitamins for the general population, focusing instead on vitamin D and on specific groups.
Were any results positive?
The cognition findings are the most interesting. Trials examining multivitamin use in older adults have reported modest improvements in memory and global cognition compared with placebo.
The effects were small and the findings have attracted genuine interest because the studies were reasonably large. They have not yet changed guidance, and the area is worth watching.
Some analyses have also suggested benefits in specific populations with poor baseline nutrition, which fits the general pattern.
Were any results negative?
The clearest harms came from individual nutrients rather than multivitamins as such. Two large trials of beta carotene in smokers found increased lung cancer rates, and one was stopped early.
A trial of vitamin E for prostate cancer prevention found a significant increase in prostate cancer in the supplemented group. Some analyses associated high dose vitamin E with increased all cause mortality.
These findings are why blanket assumptions that supplements are harmless do not survive contact with the evidence.
Why did the trials find so little?
Chiefly because of who was studied. Participants in these trials were mostly well nourished, and filling a gap that does not exist produces nothing.
Trial durations may also have been too short to detect effects on diseases developing over decades, and the modest doses in multivitamins differ from treating an identified deficiency properly.
There is also the recurring finding that isolated nutrients do not reproduce what whole foods appear to do.
What should you conclude?
That multivitamins are not a disease prevention tool, and that the honest case for taking one is narrower: covering a plausible nutritional gap in someone likely to have one.
For people eating varied food, the trials suggest very little is to be gained. For people with restricted diets, malabsorption or specific requirements, the reasoning is different and better founded.
This article is general information and not medical advice.
How should trial results be weighed?
Randomised trials are the strongest evidence available because participants are assigned by chance, which removes the confounding that makes observational supplement research so difficult to interpret.
People who take multivitamins tend to be wealthier, more active and more health conscious, so observational studies showing they are healthier tell you about the people rather than the pills. That is precisely what randomisation is designed to strip out.
Does absence of benefit mean absence of use?
No, and the distinction matters. These trials tested whether multivitamins prevent disease in well nourished people, which is a different question from whether they correct nutritional shortfalls in people who have them.
Almost nobody has run the second study properly, so the honest position is that the disease prevention claim has been tested and failed, while the gap filling rationale remains reasonable but largely untested.